Shop By
Catalog No.
Product Name
Application
Product Information
Product Citation
-
Bruton tyrosine kinase inhibitor
PCI-32765 is an orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity.- Marta G Fuster, .et al. , Pharmaceutics, 2023, Apr 7;15(4):1186 PMID: 37111671
- Simonowski A, .et al. , Biochim Biophys Acta Mol Cell Res, 2019, Dec 11;1867(4):118622 PMID: 31837347
- Carolin N. Zorn, .et al. , Sci Rep, 2018, 8: 15467 PMID: 30341350
- Li T, .et al. , Oncogene, 2018, Nov;37(47):6180-6194 PMID: 30013190
- Brittany M. Duggan, .et al. , Sci Rep, 2017, 7: 1578 PMID: 28484277
-
BTK inhibitor
ONO-4059 is a highly potent and selective oral BTK inhibitor -
Btk Inhibitor
ACP-196 is an orally available inhibitor of Bruton?€?s tyrosine kinase (BTK) with potential antineoplastic activity. It inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. -
BTK inhibitor
Olmutinib is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK). -
BTK inhibitor
Evobrutinib is a highly selective BTK inhibitor with an IC50 of 37.9 nM. It has potential anti-neoplastic activity. -
BTK inhibitor
BMS-935177 a potent BTK inhibitor with improved kinase selectivity and superior oral exposure in multiple species. should provide useful clinical efficacy in autoimmune diseases. -
BTK inhibitor
Ibrutinib Racemate (PCI-32765 Racemate) is the racemate of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with IC50 value of 0.5 nM. -
BTK inhibitor
Tirabrutinib (ONO-4059) is a highly selective, orally bioavailable BTK inhibitor with an IC50 of 2.2 nM. -
BTK inhibitor
Tirabrutinib (ONO-4059) hydrochloride is a selective and novel inhibitor of BTK with IC50 2.2 nm, Tirabrutinib binds to BTK within B cells, thereby preventing B-cell receptor signaling and impeding B-cell development.